European Commission Approves Drug for Urothelial Cancer
April 13 2022 - 12:31PM
Dow Jones News
By Isaac Taylor
Astellas Pharma Inc. and Seagen Inc. announced Wednesday that
the European Commission has approved a monotherapy for the
treatment of adult patients with locally advanced or metastatic
urothelial cancer.
The approval is for patients who have previously received a
platinum-containing chemotherapy and a PD-1/L1 inhibitor.
Urothelial cancer is the most common type of bladder cancer,
comprising 90% of cases. Globally, roughly 573,000 new cases of
bladder cancer and 212,000 deaths are reported annually.
The EC approval is supported by data from a global phase three
trial that showed an overall survival benefit compared with
chemotherapy.
Write to Isaac Taylor at isaac.taylor@wsj.com
(END) Dow Jones Newswires
April 13, 2022 12:16 ET (16:16 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astellas Pharma (PK) (USOTC:ALPMY)
Historical Stock Chart
From Dec 2024 to Jan 2025
Astellas Pharma (PK) (USOTC:ALPMY)
Historical Stock Chart
From Jan 2024 to Jan 2025
